{'fraction_non_alphanumeric': 0.027417027417027416, 'fraction_numerical': 0.010101010101010102, 'mean_word_length': 5.609523809523809, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
In vitro assessment of buffy‐coat derived platelet components suspended in SSP+ treated with the INTERCEPT Blood system

The INTERCEPT Blood System uses amotosalen‐HCl and UVA light to cross‐link DNA and RNA, thereby inhibiting pathogen replication. Although previous studies have shown that this treatment alters in vitro platelet quality, most studies have assessed apheresis platelets or platelets pooled from 5 or 6 donors. In Australia, platelets are prepared using buffy‐coats from 4 donors, with SSP+ and have lower plasma carryover than recommended by the manufacturer (32–47%). As such, it is currently unknown whether these platelet concentrates are suitable for INTERCEPT treatment.